OVAGE
RUO
20mg
pep-OVA-20mg-us
Ovagen
$75.34Out of stock
Loading product…
RUO
16mg
pep-ARA-16mg-us
ARA-290 16mg
ARA-290 (cibinetide) is an 11-amino-acid peptide modeled from the helix-B region of erythropoietin, characterized in the literature as selectively engaging the innate repair receptor without activating classic erythropoietin-receptor pathways. Collino et al. (Pharmacology & Therapeutics, 2015; PMID 25728128) reviewed this mechanism across experimental animal models and early clinical research. For Research Use Only. Not for human consumption.
$107.24Out of stock
1
For laboratory research use only · Not for human or veterinary use.
Description
About this peptide
About This Compound
ARA-290 (cibinetide) is a synthetic peptide modeled from the helix-B region of erythropoietin, designed to interact with the innate repair receptor (IRR) — a heterodimer of the erythropoietin receptor and beta-common receptor subunits — without engaging the classic erythropoietin receptor homodimer responsible for red-cell production. It has been characterized in the literature as tissue-selective, sparing the hematologic activity associated with recombinant erythropoietin. The way a master key opens a specific set of doors without touching every lock in the building, ARA-290 is described in research as activating the IRR pathway associated with tissue-protection signaling while research models report it leaving red-cell-stimulating pathways largely uninvolved.
Research Context
Collino et al. (Pharmacology & Therapeutics, 2015; PMID 25728128) reviewed the molecular mechanism of ARA-290 (pHBSP), describing its selective engagement of the innate repair receptor across a range of experimental animal models and early clinical research, despite a short plasma half-life. Bitto et al. (Biochimica et Biophysica Acta Molecular Basis of Disease, 2018; PMID 29223734) investigated cibinetide in a genetically diabetic mouse model, documenting changes in wound-tissue VEGF, phospho-Akt, and phospho-eNOS markers alongside re-epithelialization and angiogenesis measures relative to vehicle-treated animals. Brines et al. (Molecular Medicine, 2015; PMID 25387363) conducted a phase 2 study of ARA-290 in subjects with type 2 diabetes and painful neuropathy, documenting changes in hemoglobin A1c, lipid profile, and PainDetect questionnaire scores over a 56-day observation period relative to placebo.
Research Use Disclaimer
For Research Use Only. Not for human consumption.
Specifications
At a glance
- SKU
- pep-ARA-16mg-us
- Strength
- 16mg
- Form
- Lyophilized powder
- Storage
- −20 °C, protected from light
- COA
- Per lot, on file
- Availability
- Out of stock
Shipping & Storage
Handling this material
Shipping
Orders ship within 24 hours. Delivered via USPS Priority or standard FedEx unless expedited shipping is selected at checkout. Tracking is emailed on dispatch and mirrored in your account.
In-transit handling
Lyophilized vials are shelf-stable and ship at ambient temperature. Storage in our warehouse is cooled; shipment does not require refrigeration.
Long-term storage
Lyophilized vials are shelf-stable at ambient temperature; refrigeration (2–8°C) extends shelf life. Refer to the batch-specific Certificate of Analysis for material-specific storage guidance. Once reconstituted, follow the storage instructions on the batch COA. Not for human or animal consumption.
Returns
Because these are research-grade biologics, we cannot accept returns on opened vials. Damaged-in-transit shipments are replaced at no cost within 7 days of delivery.
Frequently asked
Common questions
No. Every SKU is labeled and sold strictly for laboratory research use only. These are not drugs, dietary supplements, or veterinary products. Research Use Only policy
Related
